Tempest Therapeutics Inc.

11/12/2024 | Press release | Distributed by Public on 11/12/2024 07:31

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.